Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data

As of the Nov 6, 2023 cut-off date, 26 patients had been treated, with 24 continuing with the therapy. With only 10 patients evaluable for response at the cut-off point, Merus reported a 60% response rate — including one confirmed response, two confirmed partial responses and three unconfirmed partial responses. Though treatment-emergent adverse events were reported in all patients (mostly grade 1 or 2 in severity), the combination therapy was well-tolerated by study participants. No significant overlapping ...